Digital medical services platform Teladoc Health (NYSE: TDOC) reported Q2 CY2025 results exceeding the market’s revenue expectations, but sales fell by 1.6% year on year to $631.9 million. The company expects next quarter’s revenue to be around $625 million, close to analysts’ estimates. Its GAAP loss of $0.19 per share was 27.8% above analysts’ consensus estimates.

Is now the time to buy Teladoc? Find out by accessing our full research report, it’s free.

“I’m pleased with our performance in the second quarter, with consolidated revenue and adjusted EBITDA both at the higher end of our guidance ranges. This reflects continued disciplined execution and builds on our solid results from the first quarter. We continue to work with focus and urgency to advance our strategic priorities, invest in products and capabilities, and deliver solid financial performance,” said Chuck Divita, Chief Executive Officer of Teladoc Health.

Company Overview

Founded to help people in rural areas get online medical consultations, Teladoc Health (NYSE: TDOC) is a telemedicine platform that facilitates remote doctor’s visits.

Revenue Growth

Examining a company’s long-term performance can provide clues about its quality. Any business can experience short-term success, but top-performing ones enjoy sustained growth for years. Unfortunately, Teladoc’s 4.4% annualized revenue growth over the last three years was sluggish. This fell short of our benchmark for the consumer internet sector and is a tough starting point for our analysis.

This quarter, Teladoc’s revenue fell by 1.6% year on year to $631.9 million but beat Wall Street’s estimates by 1.6%. Company management is currently guiding for a 2.4% year-on-year decline in sales next quarter.

Looking further ahead, sell-side analysts expect revenue to remain flat over the next 12 months, a deceleration versus the last three years. This projection is underwhelming and implies its products and services will see some demand headwinds.

Unless you’ve been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) stock benefiting from the rise of AI. Click here to access our free report one of our favorites growth stories.

U.S. Integrated Care Members

User Growth

As an online marketplace, Teladoc generates revenue growth by increasing both the number of users on its platform and the average order size in dollars.

Over the last two years, Teladoc’s u.s. integrated care members, a key performance metric for the company, increased by 8% annually to 102.4 million in the latest quarter. This growth rate is decent for a consumer internet business and indicates people enjoy using its offerings.

In Q2, Teladoc added 10 million u.s. integrated care members, leading to 10.8% year-on-year growth. The quarterly print was higher than its two-year result, suggesting its new initiatives are accelerating user growth.

Revenue Per User

Average revenue per user (ARPU) is a critical metric to track because it measures how much the company earns in transaction fees from each user. ARPU also gives us unique insights into a user’s average order size and Teladoc’s take rate, or "cut", on each order.

Teladoc’s ARPU fell over the last two years, averaging 7.1% annual declines. This isn’t great, but the increase in u.s. integrated care members is more relevant for assessing long-term business potential. We’ll monitor the situation closely; if Teladoc tries boosting ARPU by taking a more aggressive approach to monetization, it’s unclear whether users can continue growing at the current pace.

This quarter, Teladoc’s ARPU clocked in at $6.17. It declined 11.2% year on year, worse than the change in its u.s. integrated care members.

Key Takeaways from Teladoc’s Q2 Results

We were impressed by how significantly Teladoc blew past analysts’ EPS and EBITDA expectations this quarter. We were also glad it expanded its number of users and slightly raised its full-year revenue guidance. On the other hand, its full-year EPS and EBITDA guidance missed. Overall, this was a decent quarter. The stock traded up 4.8% to $7.88 immediately after reporting.

So should you invest in Teladoc right now? We think that the latest quarter is only one piece of the longer-term business quality puzzle. Quality, when combined with valuation, can help determine if the stock is a buy. We cover that in our actionable full research report which you can read here, it’s free.